HK Stock Market Move | LEADS BIOLABS-B(09887) rose over 5%, VILIVIN received orphan drug designation from the European Commission

LEADS BIOLABS-B(09887) surged more than 5%, reaching a 4.94% increase to 55.2 Hong Kong dollars by the time of publication, with a trading volume of 18.0035 million Hong Kong dollars. On the news front, on January 22, LEADS BIOLABS-B announced that on January 9, 2026, the European Commission (EC) granted orphan drug designation for the PD-L1/4-1BB bispecific antibody Velixin (opatasumab, LBL-024) for the treatment of extrapulmonary neuroendocrine cancer. This is the second orphan drug designation awarded to Velixin after being recognized by the U.S. Food and Drug Administration (FDA), marking another important milestone in the global development process of Velixin.